Backed by $1 million in funding from the CVS Health Foundation, the pilot initiative offers free, virtual health screenings to support aging with con ...

Hims & Hers will begin offering generic semaglutide drugs in Canada next year after Novo Nordisk lost its exclusive patent ...

This growth is fueled by a surge in startup funding and the introduction of new solutions and services, especially those designed for virtual consultations. Furthermore, integrating artificial ...

The number of reported measles cases in the United States has hit 1,288 in the first six months of this year, the most since ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...

For weight loss, weight management, and overall wellness, focus on eating healthy foods, like high-protein meals, legumes, ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Hims & Hers Health (NYSE:HIMS) shares climbed 2% on Wednesday following the announcement of its planned market entry into ...